Perioperative Complications and In-Hospital Mortality in Partial and Radical Nephrectomy Patients with Heart-Valve Replacement.

Comorbidities Heart surgery Heart-valve replacement Kidney cancer NIS

Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
25 Mar 2024
Historique:
received: 08 01 2024
accepted: 12 03 2024
medline: 25 3 2024
pubmed: 25 3 2024
entrez: 25 3 2024
Statut: aheadofprint

Résumé

In-hospital mortality and complication rates after partial and radical nephrectomy in patients with history of heart-valve replacement are unknown. Relying on the National Inpatient Sample (2000-2019), kidney cancer patients undergoing partial or radical nephrectomy were stratified according to presence or absence of heart-valve replacement. Multivariable logistic and Poisson regression models addressed adverse hospital outcomes. Overall, 39,673 patients underwent partial nephrectomy versus 94,890 radical nephrectomy. Of those, 248 (0.6%) and 676 (0.7%) had a history of heart-valve replacement. Heart-valve replacement patients were older (median partial nephrectomy 69 versus 60 years; radical nephrectomy 71 versus 63 years), and more frequently exhibited Charlson comorbidity index ≥ 3 (partial nephrectomy 22 versus 12%; radical nephrectomy 32 versus 23%). In partial nephrectomy patients, history of heart-valve replacement increased the risk of cardiac complications [odds ratio (OR) 4.33; p < 0.001), blood transfusions (OR 2.00; p < 0.001), intraoperative complications (OR 1.53; p = 0.03), and longer hospital stay [rate ratio (RR) 1.25; p < 0.001], but not in-hospital mortality (p = 0.5). In radical nephrectomy patients, history of heart-valve replacement increased risk of postoperative bleeding (OR 4.13; p < 0.001), cardiac complications (OR 2.72; p < 0.001), intraoperative complications (OR 1.53; p < 0.001), blood transfusions (OR 1.27; p = 0.02), and longer hospital stay (RR 1.12; p < 0.001), but not in-hospital mortality (p = 0.5). History of heart-valve replacement independently predicted four of twelve adverse outcomes in partial nephrectomy and five of twelve adverse outcomes in radical nephrectomy patients including intraoperative and cardiac complications, blood transfusions, and longer hospital stay. Conversely, no statistically significant differences were observed in in-hospital mortality.

Sections du résumé

BACKGROUND BACKGROUND
In-hospital mortality and complication rates after partial and radical nephrectomy in patients with history of heart-valve replacement are unknown.
PATIENTS AND METHODS METHODS
Relying on the National Inpatient Sample (2000-2019), kidney cancer patients undergoing partial or radical nephrectomy were stratified according to presence or absence of heart-valve replacement. Multivariable logistic and Poisson regression models addressed adverse hospital outcomes.
RESULTS RESULTS
Overall, 39,673 patients underwent partial nephrectomy versus 94,890 radical nephrectomy. Of those, 248 (0.6%) and 676 (0.7%) had a history of heart-valve replacement. Heart-valve replacement patients were older (median partial nephrectomy 69 versus 60 years; radical nephrectomy 71 versus 63 years), and more frequently exhibited Charlson comorbidity index ≥ 3 (partial nephrectomy 22 versus 12%; radical nephrectomy 32 versus 23%). In partial nephrectomy patients, history of heart-valve replacement increased the risk of cardiac complications [odds ratio (OR) 4.33; p < 0.001), blood transfusions (OR 2.00; p < 0.001), intraoperative complications (OR 1.53; p = 0.03), and longer hospital stay [rate ratio (RR) 1.25; p < 0.001], but not in-hospital mortality (p = 0.5). In radical nephrectomy patients, history of heart-valve replacement increased risk of postoperative bleeding (OR 4.13; p < 0.001), cardiac complications (OR 2.72; p < 0.001), intraoperative complications (OR 1.53; p < 0.001), blood transfusions (OR 1.27; p = 0.02), and longer hospital stay (RR 1.12; p < 0.001), but not in-hospital mortality (p = 0.5).
CONCLUSIONS CONCLUSIONS
History of heart-valve replacement independently predicted four of twelve adverse outcomes in partial nephrectomy and five of twelve adverse outcomes in radical nephrectomy patients including intraoperative and cardiac complications, blood transfusions, and longer hospital stay. Conversely, no statistically significant differences were observed in in-hospital mortality.

Identifiants

pubmed: 38526833
doi: 10.1245/s10434-024-15228-6
pii: 10.1245/s10434-024-15228-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, et al. Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:71–90. https://doi.org/10.6004/jnccn.2022.0001 .
doi: 10.6004/jnccn.2022.0001 pubmed: 34991070 pmcid: 10191161
Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022;82:399–410. https://doi.org/10.1016/j.eururo.2022.03.006 .
doi: 10.1016/j.eururo.2022.03.006 pubmed: 35346519
Agency for Healthcare Research and Quality, Rockville, MD. HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2008-2019 n.d. www.hcup-us.ahrq.gov/nisoverview.jsp (accessed September 2 2023).
Joudi FN, Veerasathpurush A, Kane CJ, Konety BR. Analysis of complications following partial and total nephrectomy for renal cancer in a population based sample. J Urol. 2007;177:1709–14. https://doi.org/10.1016/j.juro.2007.01.037 .
doi: 10.1016/j.juro.2007.01.037 pubmed: 17437791
Palumbo C, Knipper S, Dzyuba-Negrean C, Pecoraro A, Rosiello G, Tian Z, et al. Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. J Geriatr Oncol. 2020;11:718–23. https://doi.org/10.1016/j.jgo.2019.06.005 .
doi: 10.1016/j.jgo.2019.06.005 pubmed: 31257163
Rosiello G, Re C, Larcher A, Fallara G, Sorce G, Baiamonte G, et al. The effect of frailty on post-operative outcomes and health care expenditures in patients treated with partial nephrectomy. Eur J Surg Oncol. 2022;48:1840–7. https://doi.org/10.1016/j.ejso.2022.01.001 .
doi: 10.1016/j.ejso.2022.01.001 pubmed: 35027234
Mazzone E, Nazzani S, Preisser F, Tian Z, Marchioni M, Bandini M, et al. Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. Cancer Epidemiol. 2018;56:118–25. https://doi.org/10.1016/j.canep.2018.08.006 .
doi: 10.1016/j.canep.2018.08.006 pubmed: 30173050
Urja P, Walters RW, Vivekanandan R, Kumar M, Abdulghani S, Hari Belbase R, et al. Trends in the use of echocardiography in patients with Staphylococcus aureus bacteremia: an analysis using the Nationwide Inpatient Sample data. Echocardiography. 2019;36:1625–32. https://doi.org/10.1111/echo.14473 .
doi: 10.1111/echo.14473 pubmed: 31471983
Loh KP, Abdallah M, Shieh M-S, Stefan MS, Pekow PS, Lindenauer PK, et al. Use of inpatient palliative care services in patients with advanced cancer receiving critical care therapies. J Natl Compr Canc Netw. 2018;16:1055–64. https://doi.org/10.6004/jnccn.2018.7039 .
doi: 10.6004/jnccn.2018.7039 pubmed: 30181417 pmcid: 6553482
Mazzone E, Knipper S, Mistretta FA, Palumbo C, Tian Z, Gallina A, et al. Trends and social barriers for inpatient palliative care in patients with metastatic bladder cancer receiving critical care therapies. J Natl Compr Canc Netw. 2019;17:1344–52. https://doi.org/10.6004/jnccn.2019.7319 .
doi: 10.6004/jnccn.2019.7319 pubmed: 31693981
Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, et al. Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies. Prostate Cancer Prostatic Dis. 2020;23:260–8. https://doi.org/10.1038/s41391-019-0183-9 .
doi: 10.1038/s41391-019-0183-9 pubmed: 31685982
United States Department of Labor, U.S. Bureau of labor statistics; consumer price index. n.d. https://www.bls.gov/cpi , 2021 (accessed December 6, 2023).
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9. https://doi.org/10.1016/0895-4356(92)90133-8 .
doi: 10.1016/0895-4356(92)90133-8 pubmed: 1607900
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care. 2005;43:1130–9.
doi: 10.1097/01.mlr.0000182534.19832.83 pubmed: 16224307
R Core Team. R: A Language and Environment for Statistical Computing. R: A Language and Environment for Statistical Computing 2022. https://www.R-project.org/ (accessed August 27, 2023).
Bianchi M, Gandaglia G, Trinh Q-D, Hansen J, Becker A, Abdollah F, et al. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. Urol Oncol. 2014;32:46.e1-46.e7. https://doi.org/10.1016/j.urolonc.2013.06.010 .
doi: 10.1016/j.urolonc.2013.06.010 pubmed: 24054864
Cano Garcia C, Flammia RS, Piccinelli M, Panunzio A, Tappero S, Barletta F, et al. Differences in survival of clear cell metastatic renal cell carcinoma according to partial versus radical cytoreductive nephrectomy. Clin Genitourin Cancer. 2023. https://doi.org/10.1016/j.clgc.2023.06.003 .
doi: 10.1016/j.clgc.2023.06.003 pubmed: 37690970
Baudo A, Incesu R-B, Morra S, Scheipner L, Jannello LMI, de Angelis M, et al. Other-cause mortality, according to partial versus radical nephrectomy: age and stage analyses. Clin Genitourin Cancer. 2024;22:181–8. https://doi.org/10.1016/j.clgc.2023.10.011 .
doi: 10.1016/j.clgc.2023.10.011 pubmed: 38042729

Auteurs

Carolin Siech (C)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, Québec, Canada. siech@med.uni-frankfurt.de.
Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany. siech@med.uni-frankfurt.de.

Andrea Baudo (A)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, Québec, Canada.
Department of Urology, IRCCS Policlinico San Donato, Milan, Italy.

Mario de Angelis (M)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, Québec, Canada.
Vita-Salute San Raffaele University, Milan, Italy.
Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.

Letizia Maria Ippolita Jannello (LMI)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, Québec, Canada.
Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Università degli Studi di Milano, Milan, Italy.

Francesco Di Bello (F)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, Québec, Canada.
Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.

Jordan A Goyal (JA)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, Québec, Canada.

Zhe Tian (Z)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, Québec, Canada.

Fred Saad (F)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, Québec, Canada.

Shahrokh F Shariat (SF)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, Weill Cornell Medical College, New York, NY, USA.
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.

Nicola Longo (N)

Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.

Luca Carmignani (L)

Department of Urology, IRCCS Policlinico San Donato, Milan, Italy.
Department of Urology, IRCCS Ospedale Galeazzi - Sant'Ambrogio, Milan, Italy.

Ottavio de Cobelli (O)

Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Università degli Studi di Milano, Milan, Italy.
Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Alberto Briganti (A)

Vita-Salute San Raffaele University, Milan, Italy.
Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.

Marina Kosiba (M)

Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany.

Philipp Mandel (P)

Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany.

Luis A Kluth (LA)

Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany.

Felix K H Chun (FKH)

Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany.

Pierre I Karakiewicz (PI)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, Québec, Canada.

Classifications MeSH